RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues to outlive stage IV diagnosis of non-small cell lung cancer after treatment with RRx-001, an experimental anticancer agent with epigenetic and...
Gespeichert in:
| Veröffentlicht in: | Case Reports in Oncology 2016-01, Vol.9 (1), p.45-50 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 50 |
|---|---|
| container_issue | 1 |
| container_start_page | 45 |
| container_title | Case Reports in Oncology |
| container_volume | 9 |
| creator | Brzezniak, Christina Schmitz, Bruno A. Peterson, Paul G. Degesys, Aiste Oronsky, Bryan T. Scicinski, Jan J. Caroen, Scott Z. Carter, Corey A. |
| description | We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues to outlive stage IV diagnosis of non-small cell lung cancer after treatment with RRx-001, an experimental anticancer agent with epigenetic and immunologic activity, in the context of a phase II clinical trial called TRIPLE THREAT. Currently, no adequate treatment options exist for patients with EGFR mutation-positive tumors who have failed a 1st-generation tyrosine kinase inhibitor (erlotinib or gefitinib) treatment and do not develop a resistant mutation. Biopsy of a large pancreatic metastasis after RRx-001 demonstrated extensive necrosis with CD3+ and CD8+ immune cell infiltration that appears to correlate with prolonged survival despite end-stage disease. These results suggest that the mode of action of RRx-001 is related to immune stimulation in addition to epigenetic inhibition. |
| doi_str_mv | 10.1159/000443605 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmed_primary_26933418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A637090760</galeid><doaj_id>oai_doaj_org_article_f2fef73b198c438eb2d067837e359c9f</doaj_id><sourcerecordid>A637090760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-483d1303bd8b6b8f2cbbf70beed892714059316a4fbff1897a9b8ff11f80a00b3</originalsourceid><addsrcrecordid>eNptkk1v1DAQQCMEoqVw4I6QJU4cUuw4sRMOSKuoLSuWFoXlbNnOeNclsVdOttB_w0_FacqqlZAPtsZv3vhjkuQ1waeEFNUHjHGeU4aLJ8kxYSxLWcGLpw_WR8mLYbjGmFUFK54nRxmrKM1JeZz8aZrfKcYkXbp2r6FF633vA7oEHfxgByRdi5Z9v3eAaug6tHTGdmOQo_UOWRf30dnFeYO-7se7WPotpo32BtDl93pVo1923KIGomqUTgMa_cyvbyd_tH6xTg4QvVur7OjD8BEtUD2FGtj5ML5MnhnZDfDqfj5JfpyfrevP6erqYlkvVqkusnxM85K2hGKq2lIxVZpMK2U4VgBtWWWc5LioKGEyN8oYUlZcVpEyhJgSS4wVPUmWs7f18lrsgu1luBVeWnEX8GEjZBit7kCYzIDhVJGq1DktQWUtZrykHGhR6cpE16fZtdurHloNLr5Y90j6eMfZrdj4G5HzvOQFj4LTWbCRsZ51xkdMx9FCb7V3ED8BxIJRjivMGY4J7-eE6duGAOZQjGAx9Yg49Ehk3z483YH81xQReDcDP2XYQDgAdXM1K8SunS755r_UfZW_n2PMWw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report</title><source>DOAJ Directory of Open Access Journals</source><source>Karger Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Brzezniak, Christina ; Schmitz, Bruno A. ; Peterson, Paul G. ; Degesys, Aiste ; Oronsky, Bryan T. ; Scicinski, Jan J. ; Caroen, Scott Z. ; Carter, Corey A.</creator><creatorcontrib>Brzezniak, Christina ; Schmitz, Bruno A. ; Peterson, Paul G. ; Degesys, Aiste ; Oronsky, Bryan T. ; Scicinski, Jan J. ; Caroen, Scott Z. ; Carter, Corey A.</creatorcontrib><description>We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues to outlive stage IV diagnosis of non-small cell lung cancer after treatment with RRx-001, an experimental anticancer agent with epigenetic and immunologic activity, in the context of a phase II clinical trial called TRIPLE THREAT. Currently, no adequate treatment options exist for patients with EGFR mutation-positive tumors who have failed a 1st-generation tyrosine kinase inhibitor (erlotinib or gefitinib) treatment and do not develop a resistant mutation. Biopsy of a large pancreatic metastasis after RRx-001 demonstrated extensive necrosis with CD3+ and CD8+ immune cell infiltration that appears to correlate with prolonged survival despite end-stage disease. These results suggest that the mode of action of RRx-001 is related to immune stimulation in addition to epigenetic inhibition.</description><identifier>ISSN: 1662-6575</identifier><identifier>EISSN: 1662-6575</identifier><identifier>DOI: 10.1159/000443605</identifier><identifier>PMID: 26933418</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Antimitotic agents ; Antineoplastic agents ; Case studies ; Dosage and administration ; Drug therapy ; Epidermal growth factor receptor ; Lung cancer, Non-small cell ; Non-small cell lung cancer ; Physiological aspects ; Published: January 2016 ; RRx-001</subject><ispartof>Case Reports in Oncology, 2016-01, Vol.9 (1), p.45-50</ispartof><rights>2016 The Author(s). Published by S. Karger AG, Basel</rights><rights>COPYRIGHT 2016 S. Karger AG</rights><rights>Copyright © 2016 by S. Karger AG, Basel 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-483d1303bd8b6b8f2cbbf70beed892714059316a4fbff1897a9b8ff11f80a00b3</citedby><cites>FETCH-LOGICAL-c524t-483d1303bd8b6b8f2cbbf70beed892714059316a4fbff1897a9b8ff11f80a00b3</cites><orcidid>0000-0002-7809-6917</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748757/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748757/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2101,27634,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26933418$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brzezniak, Christina</creatorcontrib><creatorcontrib>Schmitz, Bruno A.</creatorcontrib><creatorcontrib>Peterson, Paul G.</creatorcontrib><creatorcontrib>Degesys, Aiste</creatorcontrib><creatorcontrib>Oronsky, Bryan T.</creatorcontrib><creatorcontrib>Scicinski, Jan J.</creatorcontrib><creatorcontrib>Caroen, Scott Z.</creatorcontrib><creatorcontrib>Carter, Corey A.</creatorcontrib><title>RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report</title><title>Case Reports in Oncology</title><addtitle>Case Rep Oncol</addtitle><description>We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues to outlive stage IV diagnosis of non-small cell lung cancer after treatment with RRx-001, an experimental anticancer agent with epigenetic and immunologic activity, in the context of a phase II clinical trial called TRIPLE THREAT. Currently, no adequate treatment options exist for patients with EGFR mutation-positive tumors who have failed a 1st-generation tyrosine kinase inhibitor (erlotinib or gefitinib) treatment and do not develop a resistant mutation. Biopsy of a large pancreatic metastasis after RRx-001 demonstrated extensive necrosis with CD3+ and CD8+ immune cell infiltration that appears to correlate with prolonged survival despite end-stage disease. These results suggest that the mode of action of RRx-001 is related to immune stimulation in addition to epigenetic inhibition.</description><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Case studies</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Epidermal growth factor receptor</subject><subject>Lung cancer, Non-small cell</subject><subject>Non-small cell lung cancer</subject><subject>Physiological aspects</subject><subject>Published: January 2016</subject><subject>RRx-001</subject><issn>1662-6575</issn><issn>1662-6575</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1v1DAQQCMEoqVw4I6QJU4cUuw4sRMOSKuoLSuWFoXlbNnOeNclsVdOttB_w0_FacqqlZAPtsZv3vhjkuQ1waeEFNUHjHGeU4aLJ8kxYSxLWcGLpw_WR8mLYbjGmFUFK54nRxmrKM1JeZz8aZrfKcYkXbp2r6FF633vA7oEHfxgByRdi5Z9v3eAaug6tHTGdmOQo_UOWRf30dnFeYO-7se7WPotpo32BtDl93pVo1923KIGomqUTgMa_cyvbyd_tH6xTg4QvVur7OjD8BEtUD2FGtj5ML5MnhnZDfDqfj5JfpyfrevP6erqYlkvVqkusnxM85K2hGKq2lIxVZpMK2U4VgBtWWWc5LioKGEyN8oYUlZcVpEyhJgSS4wVPUmWs7f18lrsgu1luBVeWnEX8GEjZBit7kCYzIDhVJGq1DktQWUtZrykHGhR6cpE16fZtdurHloNLr5Y90j6eMfZrdj4G5HzvOQFj4LTWbCRsZ51xkdMx9FCb7V3ED8BxIJRjivMGY4J7-eE6duGAOZQjGAx9Yg49Ehk3z483YH81xQReDcDP2XYQDgAdXM1K8SunS755r_UfZW_n2PMWw</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Brzezniak, Christina</creator><creator>Schmitz, Bruno A.</creator><creator>Peterson, Paul G.</creator><creator>Degesys, Aiste</creator><creator>Oronsky, Bryan T.</creator><creator>Scicinski, Jan J.</creator><creator>Caroen, Scott Z.</creator><creator>Carter, Corey A.</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7809-6917</orcidid></search><sort><creationdate>20160101</creationdate><title>RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report</title><author>Brzezniak, Christina ; Schmitz, Bruno A. ; Peterson, Paul G. ; Degesys, Aiste ; Oronsky, Bryan T. ; Scicinski, Jan J. ; Caroen, Scott Z. ; Carter, Corey A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-483d1303bd8b6b8f2cbbf70beed892714059316a4fbff1897a9b8ff11f80a00b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Case studies</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Epidermal growth factor receptor</topic><topic>Lung cancer, Non-small cell</topic><topic>Non-small cell lung cancer</topic><topic>Physiological aspects</topic><topic>Published: January 2016</topic><topic>RRx-001</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brzezniak, Christina</creatorcontrib><creatorcontrib>Schmitz, Bruno A.</creatorcontrib><creatorcontrib>Peterson, Paul G.</creatorcontrib><creatorcontrib>Degesys, Aiste</creatorcontrib><creatorcontrib>Oronsky, Bryan T.</creatorcontrib><creatorcontrib>Scicinski, Jan J.</creatorcontrib><creatorcontrib>Caroen, Scott Z.</creatorcontrib><creatorcontrib>Carter, Corey A.</creatorcontrib><collection>Karger Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case Reports in Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brzezniak, Christina</au><au>Schmitz, Bruno A.</au><au>Peterson, Paul G.</au><au>Degesys, Aiste</au><au>Oronsky, Bryan T.</au><au>Scicinski, Jan J.</au><au>Caroen, Scott Z.</au><au>Carter, Corey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report</atitle><jtitle>Case Reports in Oncology</jtitle><addtitle>Case Rep Oncol</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>9</volume><issue>1</issue><spage>45</spage><epage>50</epage><pages>45-50</pages><issn>1662-6575</issn><eissn>1662-6575</eissn><abstract>We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues to outlive stage IV diagnosis of non-small cell lung cancer after treatment with RRx-001, an experimental anticancer agent with epigenetic and immunologic activity, in the context of a phase II clinical trial called TRIPLE THREAT. Currently, no adequate treatment options exist for patients with EGFR mutation-positive tumors who have failed a 1st-generation tyrosine kinase inhibitor (erlotinib or gefitinib) treatment and do not develop a resistant mutation. Biopsy of a large pancreatic metastasis after RRx-001 demonstrated extensive necrosis with CD3+ and CD8+ immune cell infiltration that appears to correlate with prolonged survival despite end-stage disease. These results suggest that the mode of action of RRx-001 is related to immune stimulation in addition to epigenetic inhibition.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>26933418</pmid><doi>10.1159/000443605</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7809-6917</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-6575 |
| ispartof | Case Reports in Oncology, 2016-01, Vol.9 (1), p.45-50 |
| issn | 1662-6575 1662-6575 |
| language | eng |
| recordid | cdi_pubmed_primary_26933418 |
| source | DOAJ Directory of Open Access Journals; Karger Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antimitotic agents Antineoplastic agents Case studies Dosage and administration Drug therapy Epidermal growth factor receptor Lung cancer, Non-small cell Non-small cell lung cancer Physiological aspects Published: January 2016 RRx-001 |
| title | RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A50%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RRx-001-Induced%20Tumor%20Necrosis%20and%20Immune%20Cell%20Infiltration%20in%20an%20EGFR%20Mutation-Positive%20NSCLC%20with%20Resistance%20to%20EGFR%20Tyrosine%20Kinase%20Inhibitors:%20A%20Case%20Report&rft.jtitle=Case%20Reports%20in%20Oncology&rft.au=Brzezniak,%20Christina&rft.date=2016-01-01&rft.volume=9&rft.issue=1&rft.spage=45&rft.epage=50&rft.pages=45-50&rft.issn=1662-6575&rft.eissn=1662-6575&rft_id=info:doi/10.1159/000443605&rft_dat=%3Cgale_pubme%3EA637090760%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26933418&rft_galeid=A637090760&rft_doaj_id=oai_doaj_org_article_f2fef73b198c438eb2d067837e359c9f&rfr_iscdi=true |